Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Massachusetts
Clinical trial register · United States · industry-sponsored

Clinical Trials in Massachusetts, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 5309 Florida 4445 Illinois 2491 Georgia 2363 Arizona 2246
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca67 Novartis Pharmaceuticals66 Eli Lilly and Company52 AbbVie39 Bristol-Myers Squibb35
State
California5309 Florida4445 Illinois2491 Georgia2363 Arizona2246
All 51 states
Target enrolment
to

Trials with a site in Massachusetts

1830 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
DrugsVS-7375·Erbitux·Cetuximab·Nab-paclitaxel
Verastem, Inc.
Phase 1/2
616
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Arizona, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-06-23
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
NCT06701682Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugVilobelimab
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-06-21
Recruiting
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
NCT07016750Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc.
Phase 3
16
California, Florida, Massachusetts, Ohio, Texas
2025-06-20
Recruiting
Stryker Neurovascular
Not applicable
183
Arizona, California, Florida, Kansas, Massachusetts, New York, Ohio, Oregon
2025-06-20
Recruiting
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-06-19
Recruiting
EXACT Therapeutics AS
Phase 2
25
Arizona, California, Massachusetts, Michigan, Pennsylvania, Rhode Island
2025-06-19
Recruiting
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
NCT06658730Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta
W.L.Gore & Associates
Observational
1,500
Arizona, California, District of Columbia, Florida, Georgia, Indiana, Maryland, Massachusetts
2025-06-19
Recruiting
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
NCT06608823Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
JenaValve Technology, Inc.
Not applicable
1,016
California, District of Columbia, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-06-18
Recruiting
AERA Pediatrics Registry
NCT07071298Dysfunction of Eustachian Tube
Integra LifeSciences Corporation
Observational
300
California, Massachusetts, Michigan, Minnesota, Ohio, Pennsylvania, Texas, Utah
2025-06-17
Recruiting
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
NCT06959277Peripheral Neuropathies, Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy With Type 2 Diabetes, Balance Control in Elderly
RxFunction Inc.
Not applicable
200
Arizona, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2025-06-17
Active, closed
4Moving Biotech
Phase 2
129
Arizona, Illinois, Massachusetts
2025-06-17
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
NCT06701669Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugParidiprubart
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-06-10
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
California, Connecticut, Massachusetts, North Carolina, Texas, Virginia, Washington
2025-06-10
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
156
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Missouri
2025-06-10
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
DrugDel-brax
Avidity Biosciences, Inc.
Phase 3
200
California, Colorado, Florida, Iowa, Kansas, Maryland, Massachusetts, New York
2025-06-10
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
NCT06703073Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugsParidiprubart·Vilobelimab·Bevacizumab
PPD Development, LP
Phase 2
600
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-06-10
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Massachusetts
2025-06-09
Recruiting
HLA Demographics Study in Adults With Type 1 Diabetes
NCT06860516Diabetes Mellitus, Type I
GentiBio, Inc
Observational
200
California, Florida, Massachusetts, New York, North Carolina
2025-06-06
Recruiting
Celgene
Phase 2
200
Alabama, Arizona, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri
2025-06-05
Recruiting
Erasca, Inc.
Phase 1
600
California, Colorado, Florida, Massachusetts, New York, Texas, Virginia
2025-06-05
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
480
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts
2025-06-04
Recruiting
Stoke Therapeutics, Inc
Phase 3
170
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Massachusetts
2025-06-04
Recruiting
Sanofi
Phase 2
99
Arizona, California, Florida, Georgia, Iowa, Kansas, Massachusetts, Michigan
2025-06-03
Recruiting
MediWound Ltd
Phase 3
216
Arizona, California, District of Columbia, Florida, Massachusetts, New Jersey, New York, Ohio
2025-06-01
Recruiting
Tango Therapeutics, Inc.
Phase 1/2
183
Arizona, Colorado, District of Columbia, Florida, Illinois, Indiana, Iowa, Massachusetts
2025-05-31
Active, closed
Eli Lilly and Company
Phase 3
586
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-05-29
Recruiting
AbbVie
Phase 2
110
Florida, Kentucky, Massachusetts, Michigan, Pennsylvania, Texas
2025-05-28
Active, closed
Swedish Orphan Biovitrum
Phase 2
156
Arizona, Massachusetts, Minnesota, New York, Ohio, Texas, Utah, Washington
2025-05-28
Recruiting
Biohaven Therapeutics Ltd.
Phase 2/3
550
Alabama, California, Colorado, Connecticut, Florida, Illinois, Kansas, Massachusetts
2025-05-28
Recruiting
Regeneron Pharmaceuticals
Phase 2
297
Alabama, California, Florida, Illinois, Kansas, Kentucky, Massachusetts, Michigan
2025-05-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-05-26
Recruiting
Minima Stent System Post- Approval Study (PAS)
NCT06828770Pulmonary Artery Stenosis, Aortic Coarctation
Renata Medical
Observational
100
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-05-21
Recruiting
Eli Lilly and Company
Phase 4
279
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
Tiziana Life Sciences LTD
Phase 2
5
Massachusetts
2025-05-19
Recruiting
Astellas Gene Therapies
Observational
50
California, Illinois, Massachusetts, Ohio, Pennsylvania, Utah
2025-05-19
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts
2025-05-16
Active, closed
Amgen
Phase 1
29
California, Connecticut, Florida, Massachusetts, Missouri, North Dakota, Ohio, South Dakota
2025-05-16
Active, closed
Zura Bio Inc
Phase 2
225
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Massachusetts
2025-05-16
Recruiting
The BRAIN App (Phase 2 SBIR)
NCT06298474Dementia, Alzheimer Disease, Vascular Dementia
Hopeful Aging
Not applicable
120
Massachusetts
2025-05-15
Recruiting
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06798012Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
Phase 2
36
California, Florida, Georgia, Massachusetts, Minnesota, Missouri, Pennsylvania, Texas
2025-05-14
Active, closed
Shionogi
Phase 2
30
Illinois, Massachusetts, Washington
2025-05-13
Active, closed
PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System
NCT06133387Colorectal Lesion, Colorectal Adenoma, Colorectal Polyp, Rectal Lesion
EndoQuest Robotics, Inc.
Not applicable
56
Arizona, Florida, Massachusetts, Ohio, Texas
2025-05-13
Recruiting
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06801236Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited
Phase 1
88
California, Florida, Maryland, Massachusetts, Minnesota, Nebraska, South Carolina, Washington
2025-05-12
Recruiting
Onyx™ Liquid Embolic IDE Clinical Study
NCT06742801Peripheral Arterial Hemorrhage, Trauma, GI Bleed, Ulcer
Medtronic Endovascular
Not applicable
119
Arizona, California, Colorado, Connecticut, Illinois, Iowa, Massachusetts, Nebraska
2025-05-09
Recruiting
Biogen
Phase 3
454
Arkansas, California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Missouri
2025-05-08
Active, closed
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
NCT06907875Facioscapulohumeral Muscular Dystrophy
Epicrispr Biotechnologies, Inc.
Phase 1/2
12
California, Georgia, Maryland, Massachusetts, Utah
2025-05-08
Recruiting
Neurocrine Biosciences
Phase 3
284
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2025-05-08
Recruiting
Tagworks Pharmaceuticals BV
Phase 1
50
Arizona, Massachusetts, Pennsylvania, Texas, Virginia
2025-05-07
Recruiting
STORM Therapeutics LTD
Phase 1/2
107
California, Florida, Massachusetts, Michigan, New York, Ohio, Texas, Virginia
2025-05-05
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
DrugZanzalintinib
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Active, closed
Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)
NCT06721871Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases
DrugCrofelemer
Napo Pharmaceuticals, Inc.
Phase 2/3
6
Massachusetts
2025-05-01
Recruiting
SPYRAL GEMINI Pilot Study
NCT06907147Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
175
California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Nevada, New Jersey
2025-05-01
Active, closed
Sumitomo Pharma Switzerland GmbH
Observational
530
Massachusetts
2025-04-30
Recruiting
Eikon Therapeutics
Phase 1/2
130
Colorado, Florida, Massachusetts, Texas, Virginia
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
974
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468Post Bariatric Hypoglycemia
Amylyx Pharmaceuticals Inc.
Phase 3
75
California, Colorado, Florida, Georgia, Kansas, Massachusetts, New York, North Carolina
2025-04-29
Active, closed
Pharming Technologies B.V.
Phase 2
12
Maryland, Massachusetts, New York
2025-04-29
Recruiting
Novartis Pharmaceuticals
Phase 2
130
California, Florida, Massachusetts, Texas
2025-04-28
Recruiting
Stelexis BioSciences
Phase 1
125
California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio, Texas
2025-04-28
Recruiting
Metro International Biotech, LLC
Phase 1
32
Massachusetts
2025-04-28
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
Tyra Biosciences, Inc
Phase 1
125
California, Kansas, Maryland, Massachusetts, Michigan, New York, Tennessee
2025-04-24
Recruiting
AbbVie
Phase 2
390
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2025-04-24
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
83
California, Florida, Illinois, Louisiana, Massachusetts, New Mexico, New York, North Carolina
2025-04-23
Recruiting
Access Cannulation Trial II
NCT05490225Dialysis; Complications, Vascular Access Complication
Voyager Biomedical
Not applicable
100
Alabama, California, Massachusetts, New York, South Carolina, Texas, Virginia
2025-04-23
Recruiting
Vanda Pharmaceuticals
Phase 3
420
Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, Montana
2025-04-21
Recruiting
Angiodynamics, Inc.
Phase 4
224
Arizona, California, Louisiana, Maryland, Massachusetts, Missouri, North Carolina, Ohio
2025-04-21
Recruiting
AstraZeneca
Phase 1/2
150
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2025-04-21
Recruiting
argenx
Phase 4
30
California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Michigan, Ohio
2025-04-17
Active, closed
EluPro Antibiotic-Eluting BioEnvelope Registry
NCT06854081Cardiac Arrhythmias
Elutia Inc.
Observational
100
California, Florida, Massachusetts, Pennsylvania
2025-04-17
Recruiting
ModernaTX, Inc.
Phase 2
180
Massachusetts, Michigan, Missouri, Oklahoma, Texas
2025-04-16
Recruiting
General Biophysics LLC
Phase 1
16
Massachusetts
2025-04-16
Recruiting
Neurocrine Biosciences
Phase 3
850
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Maryland, Massachusetts
2025-04-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
605
Connecticut, Kentucky, Louisiana, Massachusetts, New York, Oklahoma, Texas, Utah
2025-04-15
Recruiting
Pyxis Oncology, Inc
Phase 1/2
220
California, Florida, Illinois, Massachusetts, New York, Oklahoma, Pennsylvania, Texas
2025-04-15
Active, closed
Definium Therapeutics US, Inc.
Phase 3
149
Arkansas, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-04-14
By invitation
Cook MyoSite
Observational
96
Massachusetts
2025-04-11
Active, closed
ASCEND CSP IDE Study
NCT06830746Heart Failure, Ventricular Arrythmia
Abbott Medical Devices
Not applicable
414
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Massachusetts, New York
2025-04-11
Active, closed
Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection
NCT06621251Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
Trellis Bioscience LLC
Phase 2
60
Arizona, California, Florida, Maryland, Massachusetts, New York, North Carolina, Texas
2025-04-08
Recruiting
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
NCT06708299Recurrent Pericarditis
Cardiol Therapeutics Inc.
Phase 3
110
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Minnesota, New York
2025-04-07
Recruiting
Amylyx Pharmaceuticals Inc.
Phase 1
48
California, District of Columbia, Florida, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2025-04-07
Recruiting
Vifor Pharma, Inc.
Phase 2
36
Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, New York, North Carolina
2025-04-06
Recruiting
FORWARD CAD IDE Study
NCT06662500Coronary Arterial Disease (CAD)
Shockwave Medical, Inc.
Not applicable
408
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts, Minnesota
2025-04-04
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Recruiting
Incyte Corporation
Phase 3
572
California, Florida, Georgia, Indiana, Kansas, Massachusetts, Michigan, Missouri
2025-04-02
Recruiting
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
NCT06346600Neovascular (Wet) Age-related Macular Degeneration
Skyline Therapeutics
Observational
83
Massachusetts, Texas, Virginia
2025-04-02
Active, closed
Shionogi
Phase 2
60
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, South Carolina, Texas
2025-04-02
Recruiting
Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb Pain
NCT06908538Amputation, Amputation of Lower Limb, Amputation of Upper Limb, Amputation, Limb Loss
AtriCure, Inc.
Observational
2,000
Massachusetts, New Hampshire, New York, Ohio, South Carolina, Wisconsin
2025-04-01
Active, closed
Shawn Talbott
Not applicable
40
Massachusetts
2025-04-01
Recruiting
Direct to Patient Minimal Risk Biospecimen and Data Collection Research
NCT07128966Healthy, Lupus, Celiac, Kidney Disease
Joined Bio
Observational
100,000
Massachusetts
2025-04-01
Recruiting
A Study of PHST001 in Advanced Solid Tumors
NCT06840886Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
DrugsMIRV·Mirvetuximab Soravtansine·Adriamycin·Topotecan
Pheast Therapeutics
Phase 1
426
California, Colorado, Connecticut, Illinois, Massachusetts, Michigan, New York, North Carolina
2025-03-31
Recruiting
Neurocrine Biosciences
Phase 3
200
Alabama, Arkansas, California, Florida, Georgia, Massachusetts, Missouri, New York
2025-03-31
Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
DrugsBBO-10203·MFOLFIRINOX·MFOLFOX6·Cetuximab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
665
California, Connecticut, Florida, Illinois, Massachusetts, New York, Tennessee, Texas
2025-03-31
Active, closed
Autobahn Therapeutics, Inc.
Phase 2
35
California, Connecticut, Florida, Illinois, Massachusetts, New Jersey, New York, Washington
2025-03-28
Recruiting
Prescient Therapeutics, Ltd.
Phase 2
115
California, Connecticut, Massachusetts, New York, Virginia
2025-03-28
Active, closed
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
NCT06892639Dystrophic Epidermolysis Bullosa
Castle Creek Biosciences, LLC.
Phase 3
32
California, Colorado, Massachusetts
2025-03-27
Recruiting
AstraZeneca
Phase 1/2
304
California, Maryland, Massachusetts, Missouri, New Jersey, Texas
2025-03-27
Recruiting
OncoC4, Inc.
Phase 1/2
387
Alabama, Arkansas, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan
2025-03-26
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2/3
150
California, Florida, Illinois, Iowa, Maryland, Massachusetts, New York, Pennsylvania
2025-03-25
Recruiting
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT07029399HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
DrugsLetrozole·Fulvestrant
NiKang Therapeutics, Inc.
Phase 1
361
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-03-25
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor
DrugAbemaciclib
Tango Therapeutics, Inc.
Phase 1/2
191
Arizona, California, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2025-03-24
Recruiting
Aldena Therapeutics
Phase 1/2
24
California, Indiana, Massachusetts, Washington
2025-03-24
Recruiting
Marengo Therapeutics, Inc.
Phase 1/2
50
California, Massachusetts, Ohio, Tennessee, Texas
2025-03-24
Recruiting
Bayer
Phase 1/2
450
Alabama, California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee
2025-03-21
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Alabama, Arizona, Arkansas, California, Colorado, Florida, Maryland, Massachusetts
2025-03-20
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-03-20
Recruiting
Daiichi Sankyo
Phase 3
582
California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts
2025-03-19
Recruiting
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2025-03-19
Recruiting
Medtronic Cardiac Ablation Solutions
Not applicable
60
Massachusetts, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-03-18
Active, closed
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT06673056Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
California, Massachusetts, Texas
2025-03-18
Recruiting
Diakonos Oncology Corporation
Phase 2
180
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio
2025-03-17
Recruiting
Sanofi
Phase 2
64
Arizona, California, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan
2025-03-17
Active, closed
Hoffmann-La Roche
Phase 4
274
California, Florida, Illinois, Massachusetts, Nevada, New Jersey, New Mexico, Tennessee
2025-03-14
Recruiting
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
NCT06950034Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2
Solu Therapeutics, Inc
Phase 1
105
California, Florida, Massachusetts, Minnesota, Oregon, Tennessee, Texas
2025-03-13
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina, Oregon
2025-03-13
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Alabama, California, District of Columbia, Florida, Georgia, Louisiana, Massachusetts, Minnesota
2025-03-12
Recruiting
AstraZeneca
Phase 2
80
Arizona, California, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota, New Jersey
2025-03-12
Recruiting
AstraZeneca
Phase 1
136
California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska, New York
2025-03-10
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
DrugZugo-cel
CRISPR Therapeutics
Phase 1
80
California, Illinois, Iowa, Louisiana, Massachusetts, Missouri, North Carolina, Oregon
2025-03-10
Active, closed
Abdera Therapeutics Inc.
Phase 1
17
California, Florida, Maryland, Massachusetts, Minnesota, New York, Texas, Utah
2025-03-10
Recruiting
Alleviant ALLAY-HFrEF Study
NCT06812533Heart Failure
Alleviant Medical, Inc.
Not applicable
350
California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri
2025-03-10
Recruiting
Halozyme Therapeutics
Phase 3
100
California, Colorado, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nevada
2025-03-07
Recruiting
AbbVie
Phase 1/2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas, Massachusetts
2025-03-06
Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
DrugsCisplatin/Carboplatin·MFOLFIRINOX·MFOLFOX6·Midazolam
Alterome Therapeutics, Inc.
Phase 1
448
Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee, Texas, Virginia
2025-03-05
Recruiting
INHANCE Stemless Reverse Shoulder IDE
NCT06323980Arthroplasty, Replacement, Shoulder
DePuy Orthopaedics
Not applicable
168
Florida, Massachusetts, Michigan, Missouri, North Carolina, Ohio, Oregon, Pennsylvania
2025-03-04
Recruiting
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
NCT06890923Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD
Phase 2
55
Massachusetts
2025-03-04
Recruiting
Novartis Pharmaceuticals
Observational
300
Massachusetts
2025-03-04
Active, closed
BicycleTx Limited
Phase 2
66
Maryland, Massachusetts, Missouri, New York, North Carolina, Oregon, Texas, Virginia
2025-03-03
Active, closed
Dasher Neuroscience Inc.
Phase 2
75
California, Massachusetts, Minnesota, New York, Tennessee, Texas
2025-03-03
Recruiting
Daiichi Sankyo
Phase 3
726
Connecticut, Illinois, Kansas, Maryland, Massachusetts, Michigan, Minnesota, New York
2025-02-27
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
Colorado, Florida, Illinois, Massachusetts, New Jersey, New York, Oregon, Tennessee
2025-02-27
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
181
Colorado, Massachusetts, New Jersey, South Carolina, Virginia
2025-02-26
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Recruiting
Amgen
Phase 3
844
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey
2025-02-25
Recruiting
Hoffmann-La Roche
Phase 1/2
53
Massachusetts, Ohio, Pennsylvania
2025-02-21
By invitation
Axsome Therapeutics, Inc.
Phase 3
236
California, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri, New Jersey
2025-02-20
Recruiting
Pikavation Therapeutics, Inc.
Phase 1/2
320
California, Massachusetts, Pennsylvania, Tennessee, Texas
2025-02-20
Active, closed
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
56
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts
2025-02-19
Active, closed
Essilor International
Not applicable
91
Illinois, Kansas, Massachusetts, New York
2025-02-18
Recruiting
March Biosciences Inc
Phase 2
46
California, Colorado, Florida, Iowa, Massachusetts, Nebraska, New York, North Carolina
2025-02-15
Active, closed
Octapharma
Observational
3,574
Massachusetts
2025-02-14
Active, closed
Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC
NCT06811909Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis
BioStem Technologies
Not applicable
71
Alabama, California, Florida, Illinois, Massachusetts, Missouri, New York, Texas
2025-02-14
Recruiting
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
MacroGenics
Phase 1
124
California, Massachusetts, Michigan, New York, Texas, Utah
2025-02-13
Recruiting
Bayer
Phase 2
111
Alabama, California, Florida, Massachusetts, Michigan, Ohio, Tennessee, Texas
2025-02-13
By invitation
Longboard Pharmaceuticals
Phase 3
324
Arkansas, California, Colorado, Florida, Idaho, Iowa, Maryland, Massachusetts
2025-02-12
Recruiting
Apple Health Study
NCT06958523Mental Health, Sleep, Exercise, Hormones
Apple Inc.
Observational
500,000
District of Columbia, Massachusetts
2025-02-12
Recruiting
ConvaTec Inc.
Not applicable
235
California, Florida, Indiana, Maryland, Massachusetts, New York, North Carolina, Pennsylvania
2025-02-12
Recruiting
Metro International Biotech, LLC
Phase 1
32
Massachusetts
2025-02-11
Recruiting
Splice Bio
Phase 1/2
57
Colorado, Florida, Massachusetts, Oregon, Texas
2025-02-11
Recruiting
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study
NCT06649955ALS - Amyotrophic Lateral Sclerosis
PathMaker Neurosystems Inc.
Not applicable
15
Massachusetts
2025-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Arizona, California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan
2025-02-07
Recruiting
Janssen Research & Development, LLC
Phase 1/2
190
Colorado, Connecticut, Florida, Louisiana, Massachusetts, Michigan, Nebraska, New York
2025-02-06
Recruiting
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
NCT06793371Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Cytokinetics
Phase 2
60
Alabama, Arizona, Arkansas, California, Florida, Illinois, Louisiana, Massachusetts
2025-02-06
Active, closed
Zura Bio Inc
Phase 2
80
California, Florida, Iowa, Massachusetts, Michigan, Texas
2025-02-06
Recruiting
ARC101 in Advanced Solid Tumors
NCT06672185Advanced Solid Tumor
Third Arc Bio
Phase 1
70
Massachusetts, Michigan, Texas
2025-02-05
By invitation
Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models
NCT06792175Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD)
Psyrin Inc.
Observational
500
Massachusetts, Ohio
2025-02-04
Recruiting
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06720987KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
DrugsKQB198·Cetuximab
Kumquat Biosciences Inc.
Phase 1
140
Arizona, Colorado, Florida, Massachusetts, Michigan, Minnesota, Ohio, Oklahoma
2025-02-04
Active, closed
Viridian Therapeutics, Inc.
Phase 3
320
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2025-02-03
Recruiting
NovoCure GmbH
Phase 3
741
Arizona, California, District of Columbia, Florida, Illinois, Kentucky, Maryland, Massachusetts
2025-02-03
Recruiting
Sequenom, Inc.
Observational
6,550
Arizona, Delaware, Florida, Louisiana, Massachusetts, New Jersey, New York, North Carolina
2025-02-02
Recruiting
Study of Olutasidenib and Temozolomide in HGG
NCT06161974High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
DrugOlutasidenib
Rigel Pharmaceuticals
Phase 2
60
Colorado, District of Columbia, Florida, Illinois, Massachusetts, North Carolina, Ohio, Pennsylvania
2025-02-01
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Massachusetts, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island
2025-01-30
Active, closed
Definium Therapeutics US, Inc.
Phase 3
245
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New Jersey, Ohio
2025-01-29
Recruiting
Zomagen Biosciences Ltd.
Phase 2
50
California, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio, Texas
2025-01-28
Active, closed
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
NCT06781983Advanced or Metastatic Solid Tumors
Innate Pharma
Phase 1
145
Massachusetts, New Jersey, New York, Texas, Virginia
2025-01-24
Recruiting
BeOne Medicines
Phase 1/2
258
Florida, Indiana, Kansas, Massachusetts, Missouri, Washington
2025-01-23
Active, closed
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement
Cogent Biosciences, Inc.
Phase 1/2
110
California, Florida, Illinois, Massachusetts, Minnesota, Ohio, Pennsylvania, Tennessee
2025-01-22
Recruiting
Neurocrine Biosciences
Phase 3
200
Arkansas, California, Florida, Massachusetts, New York, Ohio, Texas, Washington
2025-01-22
Recruiting
Biogen
Phase 1
78
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Pennsylvania, Texas
2025-01-16
Active, closed
Intellia Therapeutics
Phase 3
80
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio
2025-01-15
Active, closed
Stemline Therapeutics, Inc.
Phase 2
85
California, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey, New York
2025-01-14
Recruiting
Collagen Matrix
Observational
118
Georgia, Massachusetts
2025-01-13
Recruiting
Laminate Medical Technologies
Not applicable
300
California, Florida, Georgia, Massachusetts, Mississippi, Nevada, South Carolina, Texas
2025-01-13
Active, closed
Regenerative Ocular Immunobiologics LLC
Phase 1/2
15
California, Florida, Kentucky, Massachusetts
2025-01-10
Recruiting
BeOne Medicines
Phase 1
525
California, Florida, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-01-10
Active, closed
Immunovant Sciences GmbH
Phase 2
120
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-01-10
Recruiting
BlossomHill Therapeutics
Phase 1/2
675
Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Michigan
2025-01-09
Recruiting
Janssen Research & Development, LLC
Phase 3
750
Arizona, Arkansas, Florida, Illinois, Maryland, Massachusetts, Minnesota, New Mexico
2025-01-09
Recruiting
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer
NextCure, Inc.
Phase 1
145
California, Kentucky, Massachusetts, Missouri, New Jersey, New York, Ohio, Pennsylvania
2025-01-07
Recruiting
Compugen Ltd
Phase 1
200
Connecticut, Massachusetts, Michigan, Tennessee, Texas, Virginia
2025-01-07
Recruiting
RAPA-501 Therapy for ALS
NCT04220190Amyotrophic Lateral Sclerosis
DrugRAPA
Rapa Therapeutics LLC
Phase 2/3
41
Massachusetts
2025-01-02
Recruiting
Home Use Study of Targeted Mechanical Stimulation for Tremor Relief
NCT07078422Essential Tremor, Parkinson's Disease
Encora, Inc.
Not applicable
80
Massachusetts
2025-01-01
Recruiting
Erchonia Corporation
Not applicable
70
California, Massachusetts
2025-01-01
Recruiting
Propedix, Inc.
Phase 2
150
Massachusetts
2024-12-30
Active, closed
RHEACELL GmbH & Co. KG
Phase 3
250
Florida, Massachusetts, Minnesota
2024-12-26
Recruiting
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT06752668Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
248
Alabama, Arizona, California, Florida, Georgia, Louisiana, Massachusetts, Michigan
2024-12-23
Active, closed
ViiV Healthcare
Phase 2
229
Alabama, California, Florida, Illinois, Louisiana, Massachusetts, Michigan, Missouri
2024-12-20
Recruiting
PAQ Therapeutics, Inc.
Phase 1
300
California, Massachusetts, Michigan, Tennessee, Texas, Utah, Virginia
2024-12-19
Recruiting
Cabaletta Bio
Phase 1/2
24
California, Colorado, Florida, Illinois, Kansas, Massachusetts, Minnesota, New York
2024-12-17
Recruiting
Aura Biosciences
Phase 2
24
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, Oklahoma, Tennessee
2024-12-16
Recruiting
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
DrugsPalazestrant·Fulvestrant
Olema Pharmaceuticals, Inc.
Phase 1
180
Arizona, Colorado, Florida, Louisiana, Massachusetts, Michigan, New York, Ohio
2024-12-16
Recruiting
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
NCT06312644Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
DrugUltomiris
Alexion Pharmaceuticals, Inc.
Observational
75
Massachusetts
2024-12-16
Recruiting
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
NCT06274788Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
Fresenius Kabi
Observational
40
California, Illinois, Massachusetts, Ohio, Oklahoma, Tennessee, Texas, Washington
2024-12-15
Active, closed
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
NCT06750432Alzheimer Disease, Early Onset
ProMis Neurosciences, Inc
Phase 1
144
California, Florida, Georgia, Massachusetts, New Jersey, New York, North Carolina, Ohio
2024-12-13
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Gilead Sciences
Phase 1/2
250
Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas
2024-12-13
Recruiting
Arcturus Therapeutics, Inc.
Phase 2
33
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Massachusetts, Missouri
2024-12-12
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 1
292
Massachusetts, Michigan
2024-12-11
Active, closed
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06627179Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
Laboratoires Thea
Phase 2
81
California, Florida, Georgia, Massachusetts, Michigan, Oregon, Pennsylvania, Texas
2024-12-11
Active, closed
Definium Therapeutics US, Inc.
Phase 3
214
Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, New Jersey
2024-12-11
Recruiting
Deciphera Pharmaceuticals, LLC
Phase 1/2
120
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Minnesota, New York
2024-12-10
Active, closed
Amgen
Phase 3
707
Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Michigan
2024-12-09
Recruiting
Teleflex
Observational
2,500
Alabama, California, Massachusetts
2024-12-08
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New Jersey, New York
2024-12-06
Recruiting
SNIPR Biome Aps.
Phase 1/2
66
California, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Texas, Washington
2024-12-04
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Arizona, California, District of Columbia, Illinois, Indiana, Kansas, Maryland, Massachusetts
2024-12-03
Active, closed
Victoria Collotta
Not applicable
15
Massachusetts
2024-12-03
Active, closed
AstraZeneca
Phase 3
181
California, Illinois, Massachusetts, Missouri
2024-12-03
Active, closed
Ultragenyx Pharmaceutical Inc
Phase 3
129
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, New York
2024-12-03
Recruiting
A Study of RSLV-132 in Females With Sjögren's Disease
NCT06440525Primary Sjögren Syndrome
Resolve Therapeutics
Phase 2
106
California, Florida, Illinois, Iowa, Massachusetts, New Mexico, North Carolina, Pennsylvania
2024-12-01
Active, closed
CereVasc Inc
Not applicable
230
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Massachusetts
2024-11-26
Recruiting
Adcendo ApS
Phase 1
210
Arkansas, Connecticut, Massachusetts, Missouri, New York, Texas
2024-11-25
Active, closed
Novartis Pharmaceuticals
Phase 4
24
California, Colorado, Illinois, Massachusetts
2024-11-25
Recruiting
Intra-Cellular Therapies, Inc.
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2024-11-22
Active, closed
Sanofi
Phase 1/2
66
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada
2024-11-21
Recruiting
Deciphera Pharmaceuticals, LLC
Phase 2
48
California, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts, Michigan
2024-11-21
Recruiting
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
DrugsTORL-1-23·Pegfilgrastim
TORL Biotherapeutics, LLC
Phase 2
230
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2024-11-20
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
25
Colorado, Massachusetts, South Dakota, Texas
2024-11-19
Active, closed
Victoria Collotta
Not applicable
40
Massachusetts
2024-11-18
Active, closed
Pfizer
Phase 3
200
Arizona, California, Colorado, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-11-15
Recruiting
Precision BioSciences, Inc.
Phase 1
45
Massachusetts
2024-11-14
Recruiting
Genentech, Inc.
Phase 1
410
California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Michigan, New York
2024-11-14
Recruiting
Daiichi Sankyo
Phase 1
150
Massachusetts, New York, Tennessee
2024-11-14
Active, closed
Bluejay Diagnostics, Inc.
Observational
700
Florida, Massachusetts, North Carolina, Tennessee, Utah
2024-11-12
By invitation
MedRhythms, Inc.
Not applicable
30
Georgia, Massachusetts
2024-11-12
By invitation
Xeltis Hemodialysis Access Graft (aXess) US Study
NCT06494631End Stage Renal Disease
Xeltis
Not applicable
140
Arizona, Florida, Massachusetts, Mississippi, North Carolina, Texas
2024-11-11
By invitation
Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy
NCT06696456Otoferlin Gene-mediated Hearing Loss
Akouos, Inc.
Observational
30
Iowa, Massachusetts, Pennsylvania
2024-11-11
Recruiting
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc.
Phase 1
65
Massachusetts, New York, Texas
2024-11-08
Active, closed
Alnylam Pharmaceuticals
Phase 1/2
89
Alabama, California, Florida, Indiana, Massachusetts, Minnesota, Missouri, North Carolina
2024-11-07
Recruiting
argenx
Observational
680
California, Florida, Illinois, Iowa, Kansas, Kentucky, Massachusetts, Michigan
2024-11-04
Recruiting
PULSED AF Post-Approval Study
NCT06578104Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
580
Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan, Nebraska, New York
2024-11-04
Recruiting
Coherus Oncology, Inc.
Phase 4
100
Arkansas, California, Georgia, Massachusetts, Michigan, New York, Ohio, Pennsylvania
2024-11-01
Recruiting
Palette Life Sciences, Inc.
Not applicable
84
Arizona, California, Florida, Georgia, Massachusetts, New Jersey, Ohio, Pennsylvania
2024-10-31
Active, closed
Dren Bio
Phase 1
81
California, Florida, Georgia, Idaho, Indiana, Massachusetts, Michigan, Pennsylvania
2024-10-30
Recruiting
Abivax S.A.
Phase 2
212
Alabama, Arizona, California, Colorado, Florida, Illinois, Iowa, Massachusetts
2024-10-30
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
California, Florida, Indiana, Massachusetts, Missouri, New York, Tennessee, Texas
2024-10-29
Recruiting
The THOR IDE Study
NCT05916950Peripheral Artery Disease, Peripheral Artery Stenosis, Peripheral Artery Calcification, PAD
Philips Clinical & Medical Affairs Global
Not applicable
155
California, Colorado, Florida, Iowa, Louisiana, Maine, Massachusetts, Michigan
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
96
California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, Ohio
2024-10-29
Active, closed
BioPorto Diagnostics
Observational
800
Alabama, California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New Mexico
2024-10-28
Active, closed
Denali Therapeutics Inc.
Phase 2
50
California, Florida, Massachusetts, New York, Washington
2024-10-24
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Massachusetts
2024-10-24
Recruiting
Shoulder Innovations Clinical Data Registry
NCT06754150Shoulder Arthroplasty
Shoulder Innovations
Observational
2,500
Alabama, California, Colorado, Florida, Georgia, Maryland, Massachusetts, Michigan
2024-10-23
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
320
California, Florida, Massachusetts, Nevada, New Jersey, North Carolina, Texas
2024-10-22
Active, closed
Abcuro, Inc.
Phase 2/3
270
Arizona, California, Connecticut, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
2024-10-21
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 1/2
48
California, Colorado, Maryland, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2024-10-21
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Recruiting
Supportive Care Intervention for Outpatient Stem Cell Transplant Patients
NCT06564233Hematopoietic Stem Cell Transplantation, Cancer
Victor Wang
Not applicable
90
Massachusetts
2024-10-21
Recruiting
Thrombolex, Inc.
Not applicable
500
Arizona, Florida, Georgia, Illinois, Indiana, Massachusetts, Mississippi, New Hampshire
2024-10-17
Active, closed
Novartis Pharmaceuticals
Phase 2
251
California, Florida, Georgia, Kansas, Massachusetts, Nebraska, New York, North Carolina
2024-10-17
Active, closed
Amgen
Phase 1
21
California, Florida, Georgia, Maryland, Massachusetts, Minnesota, North Carolina, Oklahoma
2024-10-16
Active, closed
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Florida, Hawaii, Illinois, Maryland, Massachusetts
2024-10-16
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington
2024-10-15
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 3
24
Alabama, Florida, Massachusetts, Michigan, Pennsylvania, Texas, Wisconsin
2024-10-14
Active, closed
Ipsen
Observational
424
California, Colorado, Connecticut, Florida, Massachusetts, New Jersey, New York, North Carolina
2024-10-14
Recruiting
HistoSonics, Inc.
Observational
5,000
California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts, Michigan
2024-10-14
Active, closed
MeiraGTx Ocular UK Ltd
Phase 2
24
Massachusetts, Michigan
2024-10-10
Active, closed
Incyte Corporation
Phase 3
346
Arizona, California, Florida, Kentucky, Maryland, Massachusetts, Michigan, New Hampshire
2024-10-10
Active, closed
Sonoma Biotherapeutics, Inc.
Phase 1
24
Massachusetts, Minnesota, Missouri, New York, North Carolina, Texas
2024-10-09
Recruiting
Study of ACR-2316 in Specific Advanced Solid Tumors
NCT06667141Specific Advanced Solid Tumors
Acrivon Therapeutics
Phase 1/2
100
Arizona, California, Colorado, Florida, Massachusetts, Michigan, New York, North Carolina
2024-10-08
Recruiting
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Phase 1
256
California, Florida, Kansas, Massachusetts, Michigan, Missouri, New York, North Carolina
2024-10-03
Active, closed
Sumitomo Pharma America, Inc.
Observational
12
Massachusetts
2024-10-03
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
349
California, District of Columbia, Florida, Illinois, Kansas, Massachusetts, Michigan, Minnesota
2024-10-02
Recruiting
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
NCT06561048Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
DrugsBelinostat·Pralatrexate·Soquelitinib
Corvus Pharmaceuticals, Inc.
Phase 3
150
California, Connecticut, Florida, Georgia, Illinois, Iowa, Maryland, Massachusetts
2024-10-02
Recruiting
VIS, Inc.
Phase 3
75
Florida, Massachusetts, New Jersey, New York
2024-09-30
Active, closed
AstraZeneca
Phase 3
310
California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas
2024-09-30
Recruiting
GlaxoSmithKline
Phase 1
845
California, Colorado, Connecticut, Indiana, Massachusetts, Michigan, New Jersey, South Carolina
2024-09-30
By invitation
Sanofi
Phase 2
900
Arizona, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, North Carolina
2024-09-30
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Mississippi
2024-09-26
Recruiting
Pfizer
Phase 2
48
California, Colorado, Indiana, Kentucky, Massachusetts, North Carolina, Texas
2024-09-25
Active, closed
ADVENT Post Approval Study
NCT06431815Paroxysmal Atrial Fibrillation
Boston Scientific Corporation
Observational
228
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Louisiana, Massachusetts
2024-09-25
Active, closed
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
DrugSotagliflozin
Lexicon Pharmaceuticals
Phase 3
500
Arizona, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts
2024-09-24
Active, closed
Hoffmann-La Roche
Phase 3
338
Arizona, California, Connecticut, Florida, Illinois, Maine, Massachusetts, Michigan
2024-09-23
Recruiting
Autobahn Therapeutics, Inc.
Phase 2
230
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts
2024-09-20
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Tennessee
2024-09-19
Active, closed
Biodesix, Inc.
Observational
4,000
Florida, Kentucky, Massachusetts, Pennsylvania
2024-09-19
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
DrugsDoxorubicin·Paclitaxel
NiKang Therapeutics, Inc.
Phase 1
238
Arkansas, California, Colorado, Florida, Georgia, Kansas, Massachusetts, New Jersey
2024-09-19
Active, closed
Regeneron Pharmaceuticals
Phase 2
151
California, Colorado, Connecticut, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2024-09-18
Active, closed
argenx
Phase 3
141
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Michigan, New Jersey
2024-09-18
Recruiting
AstraZeneca
Phase 1/2
174
California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington
2024-09-18
Active, closed
VistaGen Therapeutics, Inc.
Phase 3
238
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2024-09-16
Recruiting
Regeneron Pharmaceuticals
Phase 2
116
Maryland, Massachusetts, Michigan, New York, Pennsylvania, Washington
2024-09-16
Recruiting
Spirovant Sciences, Inc.
Phase 1/2
15
Kansas, Massachusetts, New York, Pennsylvania
2024-09-16
Recruiting
NaviFUS Corporation
Phase 1/2
8
California, Massachusetts, Virginia
2024-09-13
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-09-12
Recruiting
AVAVA MIRIA General Use
NCT06868615Acne, Acne Scars - Mixed Atrophic and Hypertrophic, Scars, Wrinkle
AVAVA, Inc.
Not applicable
200
Massachusetts
2024-09-11
Recruiting
Abbott Medical Devices
Not applicable
100
Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Minnesota
2024-09-11
Active, closed
Noema Pharma AG
Phase 2
164
Arizona, California, Florida, Georgia, Massachusetts, Michigan, Missouri, Nebraska
2024-09-10
By invitation
Candela Corporation
Not applicable
150
Massachusetts
2024-09-09
Recruiting
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
NCT06370182Acute Ischemic Stroke From Large Vessel Occlusion
Anaconda Biomed S.L.
Not applicable
327
Florida, Georgia, Illinois, Iowa, Massachusetts, New York, Oregon, Pennsylvania
2024-09-09
Recruiting
Lakefront Biotherapeutics NV
Phase 3
546
Massachusetts
2024-09-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Alabama, California, Illinois, Iowa, Kentucky, Massachusetts, Missouri, North Carolina
2024-09-04
Recruiting
Kardion Inc
Not applicable
310
Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Indiana, Massachusetts
2024-09-03
Recruiting
ATLAS (AltaValve) Pivotal Trial
NCT06465745Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation
4C Medical Technologies, Inc.
Not applicable
450
Arizona, California, Florida, Georgia, Louisiana, Maryland, Massachusetts, Michigan
2024-09-03
Not yet open
Abbott Nutrition
Not applicable
321
Arizona, Arkansas, Connecticut, Florida, Massachusetts, Missouri, New Mexico, New York
2024-09
Active, closed
Sanofi
Phase 2
229
Arizona, California, Colorado, Florida, Idaho, Kansas, Massachusetts, Michigan
2024-08-29
Recruiting
Bayer
Phase 3
444
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2024-08-28
Active, closed
Viridian Therapeutics, Inc.
Phase 3
132
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2024-08-27
Active, closed
Viridian Therapeutics, Inc.
Phase 3
204
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2024-08-27
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
93
Alabama, Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New Jersey
2024-08-26
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia
2024-08-22
Recruiting
Opna Bio LLC
Phase 1
130
Arizona, California, Georgia, Kansas, Massachusetts, Michigan, New York, North Carolina
2024-08-22
Recruiting
Octapharma
Phase 3
120
California, Florida, Massachusetts, North Carolina, Ohio, Oklahoma, Texas
2024-08-21
Active, closed
Rgenta Therapeutics Inc
Phase 1
105
Massachusetts, Michigan, New York, Texas, Virginia, Washington
2024-08-19
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2024-08-16
Recruiting
Novartis Pharmaceuticals
Phase 1/2
161
Alabama, Florida, Massachusetts, New York, North Carolina, Pennsylvania, Rhode Island, Texas
2024-08-15
Recruiting
Eli Lilly and Company
Phase 1
48
Florida, Georgia, Massachusetts, New Jersey, North Carolina
2024-08-15
Active, closed
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
Circle Pharma
Phase 1
220
Florida, Massachusetts, Michigan, Nevada, Ohio, Oregon, Tennessee, Texas
2024-08-14
Recruiting
EFS of the DUO System for Tricuspid Regurgitation
NCT05913908Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
CroiValve Limited
Not applicable
15
Arizona, California, Georgia, Illinois, Kansas, Maine, Massachusetts, Minnesota
2024-08-13
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Minnesota, Missouri
2024-08-13
Active, closed
Genentech, Inc.
Phase 2
118
Arkansas, Colorado, Florida, Indiana, Iowa, Maryland, Massachusetts, Nebraska
2024-08-09
Recruiting
AbbVie
Phase 3
110
California, Colorado, Connecticut, Illinois, Indiana, Massachusetts, Minnesota, New York
2024-08-08
Active, closed
Pfizer
Observational
450
Alabama, California, Florida, Iowa, Maryland, Massachusetts, Michigan, Minnesota
2024-08-07
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
220
California, Colorado, Massachusetts, Michigan, New York, Ohio, Tennessee, Texas
2024-08-07
Recruiting
Convergent Therapeutics
Phase 2
93
California, Massachusetts, Missouri, Nebraska, New York, North Carolina, Ohio
2024-08-06
Recruiting
Regeneron Pharmaceuticals
Phase 1
90
Massachusetts, New Jersey, New York, Pennsylvania, Utah
2024-08-06
Recruiting
Tempus AI
Observational
500
California, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2024-08-01
Active, closed
UniQure Biopharma B.V.
Phase 1/2
20
Arizona, California, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2024-08-01
Active, closed
Belite Bio, Inc
Phase 2/3
60
Arizona, California, Florida, Massachusetts, Minnesota, New York, North Carolina, Pennsylvania
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Michigan, North Carolina
2024-07-31
Active, closed
Ultragenyx Pharmaceutical Inc
Phase 3
255
California, Georgia, Illinois, Massachusetts, New York
2024-07-31
Recruiting
Gilead Sciences
Phase 1
154
California, Massachusetts, Texas, Virginia
2024-07-26
Active, closed
Ferrer Internacional S.A.
Phase 2
241
California, Colorado, Florida, Georgia, Massachusetts, Michigan, New York, North Carolina
2024-07-23
Active, closed
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06137807Tricuspid Regurgitation, Tricuspid Valve Disease
P+F Products + Features USA Inc.
Not applicable
50
Arizona, California, Florida, Illinois, Indiana, Louisiana, Massachusetts, Minnesota
2024-07-23
Recruiting
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
DrugRYZ101
RayzeBio, Inc.
Phase 1/2
64
Arizona, California, Colorado, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-07-19
Recruiting
Jazz Pharmaceuticals
Phase 3
286
California, Colorado, Florida, Georgia, Kansas, Kentucky, Louisiana, Massachusetts
2024-07-19
Recruiting
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
NCT06521554Locally Advanced Solid Tumor, Metastatic Solid Tumor
Nuvalent Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Maryland, Massachusetts, Michigan, Missouri
2024-07-18
Recruiting
Bristol-Myers Squibb
Phase 1/2
224
Alabama, California, Connecticut, Georgia, Illinois, Kansas, Maryland, Massachusetts
2024-07-17
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
38
California, Illinois, Indiana, Massachusetts, Missouri, New York, Ohio, Utah
2024-07-17
Active, closed
Vor Biopharma
Phase 3
191
Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts
2024-07-17
Active, closed
Innosphere
Not applicable
146
Massachusetts, Minnesota, Texas
2024-07-15
Recruiting
Bracco Diagnostics, Inc
Phase 3
106
California, Georgia, Massachusetts, Oregon, Texas
2024-07-10
Recruiting
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Context Therapeutics Inc.
Phase 1
156
Arkansas, California, Colorado, Massachusetts, Nebraska, New Jersey, New York, North Carolina
2024-07-10
Recruiting
GlaxoSmithKline
Phase 1
675
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2024-07-02
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2024-07-01
Recruiting
Curadel Surgical Innovations, Inc.
Phase 2/3
336
California, Florida, Massachusetts
2024-06-28
Recruiting
Boehringer Ingelheim
Phase 1/2
768
California, Connecticut, Florida, Illinois, Indiana, Iowa, Massachusetts, Michigan
2024-06-28
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
California, Connecticut, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2024-06-25
Recruiting
SpliSense Ltd.
Phase 2
64
California, Colorado, Massachusetts
2024-06-24
Recruiting
Medtronic - MITG
Not applicable
278
Connecticut, Illinois, Massachusetts, New Jersey, New York
2024-06-21
Recruiting
SterileCare Inc.
Not applicable
124
Massachusetts, Nebraska, New York, North Carolina, Ohio, Texas, Washington
2024-06-21
Recruiting
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
NCT06445322Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
Ascidian Therapeutics, Inc
Observational
50
California, Florida, Maryland, Massachusetts, Michigan, Ohio, Texas
2024-06-20
Active, closed
Sanofi
Phase 2
185
Alabama, Arizona, California, Colorado, Connecticut, Florida, Indiana, Massachusetts
2024-06-20
Recruiting
Nipro Vascular Innovations Americas, Inc
Not applicable
159
Arizona, California, Florida, Georgia, Hawaii, Louisiana, Massachusetts, New Jersey
2024-06-20
Recruiting
Beam Therapeutics Inc.
Phase 1/2
192
Alabama, Massachusetts, South Carolina
2024-06-19
Recruiting
60 Degrees Pharmaceuticals LLC
Phase 2
33
Massachusetts
2024-06-17
Active, closed
Food Trial to Evaluate the Kinetics of the Medical Foods SBD111 and SBD121 Persistence in Healthy Adults
NCT06614166Product Persistence in GI Tract, Kinetics, Rheumatoid Arthritis (RA), Bone Density
Solarea Bio, Inc
Not applicable
40
Massachusetts
2024-06-14
Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
NCT06557265Lupus Nephritis, Primary Membranous Nephropathy
DrugNKX019
Nkarta, Inc.
Phase 1/2
120
Arkansas, California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan
2024-06-13
Recruiting
Gilead Sciences
Phase 1/2
250
Alabama, Connecticut, Georgia, Kentucky, Massachusetts, New Jersey, New York, Ohio
2024-06-12
Recruiting
UniQure Biopharma B.V.
Phase 1/2
12
Alabama, Arizona, California, Florida, Kansas, Maryland, Massachusetts, Michigan
2024-06-12
Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
ModeX Therapeutics, An OPKO Health Company
Phase 1/2
330
Colorado, Florida, Massachusetts, Tennessee, Texas
2024-06-12
Recruiting
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964Schizophrenia, Cognitive Impairment
Alto Neuroscience
Phase 2
82
California, Florida, Georgia, Illinois, Maryland, Massachusetts, New York
2024-06-11
Recruiting
Vectorious Medical Technologies Ltd.
Not applicable
10
Massachusetts
2024-06-11
Recruiting
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
NCT06467344Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Ascidian Therapeutics, Inc
Phase 1/2
15
California, Florida, Maryland, Massachusetts, Michigan, Ohio, Oregon, Pennsylvania
2024-06-11
Active, closed
Natera, Inc.
Not applicable
250
California, Colorado, Florida, Kansas, Massachusetts, Michigan, New York, North Carolina
2024-06-10
Active, closed
Biogen
Observational
10,500
Massachusetts
2024-06-08
Recruiting
X4 Pharmaceuticals
Phase 3
176
Arizona, California, Florida, Georgia, Iowa, Massachusetts, Michigan, Missouri
2024-06-06
Active, closed
NOxy Health Products, LLC
Phase 1
40
Arizona, Florida, Massachusetts, Ohio, Texas
2024-06-06
Active, closed
Amgen
Phase 3
563
Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2024-06-05
Active, closed
Nexcella Inc.
Phase 1/2
45
California, Georgia, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New York
2024-06-05
Active, closed
Windtree Therapeutics
Phase 1/2
20
Massachusetts, Oregon
2024-06-01
Active, closed
Amgen
Phase 1/2
94
Arkansas, California, Florida, Illinois, Massachusetts, Nevada, Pennsylvania, Texas
2024-05-30
Recruiting
CraniSeal Post Approval Study
NCT06406790Leak, Cerebrospinal Fluid
Pramand LLC
Phase 4
224
California, Florida, Georgia, Massachusetts, Minnesota, New York, South Carolina
2024-05-29
Active, closed
Amgen
Phase 1
120
California, Colorado, Connecticut, Illinois, Indiana, Kentucky, Massachusetts, Missouri
2024-05-29
Recruiting
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC
DrugsRMC-9805·MFOLFIRINOX·MFOLFOX6·Folfox
Revolution Medicines, Inc.
Phase 1/2
1,130
Arizona, California, Colorado, Connecticut, Florida, Kansas, Maryland, Massachusetts
2024-05-24
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Arizona, California, Florida, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2024-05-24
Recruiting
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
NCT06451497Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
Zumutor Biologics Inc.
Phase 1
100
Massachusetts, Texas
2024-05-22
Active, closed
Philogen S.p.A.
Phase 2
90
Illinois, Massachusetts, New York, Pennsylvania, Texas, Virginia
2024-05-22
Recruiting
Daiichi Sankyo
Phase 3
540
Arkansas, California, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan
2024-05-21
Active, closed
Syndax Pharmaceuticals
Phase 1
96
Arizona, California, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2024-05-21
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
DrugsTucatinib·Disitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2024-05-20
Active, closed
Alnylam Pharmaceuticals
Phase 2
210
California, Colorado, Connecticut, Florida, Illinois, Kentucky, Louisiana, Massachusetts
2024-05-17
Recruiting
Hercules
Observational
100,000
Massachusetts
2024-05-17
Active, closed
Regeneron Pharmaceuticals
Phase 1
6
Florida, Georgia, Massachusetts, New York, Pennsylvania
2024-05-17
Recruiting
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
NCT06116110Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma
Miltenyi Biomedicine GmbH
Observational
150
Arizona, California, Connecticut, Illinois, Kansas, Maryland, Massachusetts, North Carolina
2024-05-15
Active, closed
Novartis Pharmaceuticals
Phase 1
42
California, Colorado, Massachusetts, New York, Ohio, Utah
2024-05-15
Recruiting
Encoded Therapeutics
Phase 1/2
47
California, Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina
2024-05-14
Active, closed
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugsKeytruda·Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2/3
410
California, Delaware, Florida, Illinois, Kentucky, Massachusetts, Michigan, Missouri
2024-05-14
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
858 Therapeutics, Inc.
Phase 1/2
120
Arizona, Connecticut, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio
2024-05-13
Active, closed
AstraZeneca
Phase 4
1,511
California, Kentucky, Massachusetts, Michigan, Minnesota, North Carolina, Pennsylvania, Texas
2024-05-10
Recruiting
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
NCT06551129Obstructive Hypertrophic Cardiomyopathy
DrugMavacamten
Bristol-Myers Squibb
Observational
118
Massachusetts
2024-05-10
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926Melanoma Stage IV, Solid Tumor
Georgiamune Inc
Phase 1/2
117
Arizona, California, Massachusetts, Montana, New York, Ohio, Tennessee, Virginia
2024-05-09
Active, closed
Helius Medical Inc
Not applicable
30
Florida, Georgia, Massachusetts, New York
2024-05-01
Active, closed
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
NCT06294236Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
DrugsSC291·Fludarabine·Cyclophosphamide
Sana Biotechnology
Phase 1
7
Colorado, Georgia, Maryland, Massachusetts, Washington
2024-04-29
Active, closed
Erasca, Inc.
Phase 3
78
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2024-04-29
Recruiting
Axsome Therapeutics, Inc.
Phase 3
450
California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri
2024-04-26
Recruiting
Study of REM-422 in Patients With AML or Higher Risk MDS
NCT06297941Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
DrugREM-422
Remix Therapeutics
Phase 1
100
California, Florida, Massachusetts, New York, Texas
2024-04-26
Recruiting
Janssen Research & Development, LLC
Phase 1/2
287
California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Missouri
2024-04-22
Active, closed
RevBio
Not applicable
20
Massachusetts, Tennessee
2024-04-18
By invitation
Pivotal Trial of the Boomerang Catheter for pDVA
NCT06311773Chronic Limb-Threatening Ischemia
Aveera Medical, Inc.
Not applicable
120
California, Delaware, Florida, Illinois, Louisiana, Massachusetts, New Hampshire, New Jersey
2024-04-16
Recruiting
Medtronic Neurovascular Clinical Affairs
Not applicable
300
California, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa, Massachusetts
2024-04-16
Recruiting
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
NCT05908331In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
Concept Medical Inc.
Not applicable
492
Alabama, Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Minnesota
2024-04-16
Recruiting
Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.
NCT05796908Arthritis, Unstable Radial Head, Proximal Radioulnar Joint Instability, Decreased Motion at the Proximal Radioulnar Joint and/or the Radio-humeral Joint
Aptis Medical
Not applicable
84
Indiana, Kentucky, Massachusetts, Ohio, Pennsylvania, Wisconsin
2024-04-12
Active, closed
Edgewise Therapeutics, Inc.
Phase 2
79
California, Georgia, Massachusetts, Michigan, Missouri, New Jersey, New York, North Carolina
2024-04-11
Active, closed
Merck Sharp & Dohme LLC
Phase 2
272
California, Connecticut, Massachusetts, New York, North Carolina, Pennsylvania, Texas
2024-04-10
Recruiting
Tr1X, Inc.
Phase 1
36
California, Massachusetts, Minnesota, New York, Washington
2024-04-08
Active, closed
Amgen
Phase 3
434
Arizona, California, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri
2024-04-08
Recruiting
A Study of Sovilnesib in Subjects With Ovarian Cancer
NCT06084416High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
Volastra Therapeutics, Inc.
Phase 1
150
Alabama, Arkansas, California, Georgia, Maryland, Massachusetts, New York, Oklahoma
2024-04-04
Active, closed
AstraZeneca
Phase 2
103
California, District of Columbia, Florida, Georgia, Hawaii, Illinois, Maryland, Massachusetts
2024-04-04
Recruiting
CytomX Therapeutics
Phase 1
160
Colorado, Massachusetts, New York, North Carolina, Tennessee, Texas, Virginia
2024-04-02
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
348
Alabama, California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Nebraska
2024-04-01
Recruiting
AbbVie
Phase 1/2
76
Florida, Massachusetts, Minnesota, New York, North Carolina, Oregon, Tennessee, Washington
2024-04-01
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Alabama, Arizona, California, Florida, Georgia, Louisiana, Massachusetts, Minnesota
2024-03-29
Recruiting
Splice Bio
Observational
75
California, Colorado, Florida, Georgia, Maryland, Massachusetts, Michigan, New York
2024-03-29
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
120
Alabama, California, Colorado, Connecticut, Kansas, Massachusetts, Missouri, New Jersey
2024-03-28
Active, closed
OsteoGen Plug vs. Freeze-dried Bone Allograft With Collagen Barrier
NCT06447844Nonterminal Premolar Needing Extraction
McGuire Institute
Not applicable
70
Colorado, Massachusetts, Michigan, Nebraska, Tennessee, Texas, Wisconsin
2024-03-28
Recruiting
Genetix Biotherapeutics Inc.
Observational
120
Massachusetts, Pennsylvania, Texas
2024-03-27
Recruiting
Tenaya Therapeutics
Phase 1
15
California, Colorado, Maryland, Massachusetts, Minnesota, New York, Ohio
2024-03-26
Active, closed
TG Therapeutics, Inc.
Observational
16
California, Georgia, Massachusetts, North Carolina, Tennessee
2024-03-26
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
Iambic Therapeutics, Inc
Phase 1
383
California, Colorado, Florida, Illinois, Massachusetts, Michigan, Missouri, New Hampshire
2024-03-25
Active, closed
Gilead Sciences
Phase 3
577
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2024-03-25
Recruiting
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
AstraZeneca
Phase 1
108
California, Florida, Illinois, Kansas, Massachusetts, Missouri, New York, Oregon
2024-03-22
Active, closed
Edgewise Therapeutics, Inc.
Phase 2
43
California, Florida, Massachusetts, Missouri, North Carolina, Ohio
2024-03-22
Active, closed
Cook MyoSite
Phase 3
200
California, Florida, Georgia, Illinois, Indiana, Louisiana, Massachusetts, Michigan
2024-03-21
Active, closed
Bristol-Myers Squibb
Phase 2
310
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, New Hampshire
2024-03-20
Recruiting
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
Compass Therapeutics
Phase 1
85
Florida, Georgia, Indiana, Massachusetts, New York, Tennessee, Washington
2024-03-19
Active, closed
Beacon Therapeutics
Phase 2/3
85
Arizona, California, Florida, Indiana, Maryland, Massachusetts, Minnesota, North Carolina
2024-03-14
Recruiting
Eli Lilly and Company
Phase 3
90
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Recruiting
Janssen Research & Development, LLC
Phase 3
120
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Recruiting
AstraZeneca
Phase 1/2
60
California, Florida, Georgia, Kansas, Massachusetts, Missouri, New Jersey, New York
2024-03-12
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2024-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New Jersey
2024-03-07
Recruiting
Sonoma Biotherapeutics, Inc.
Phase 1
48
Arizona, California, Colorado, Illinois, Massachusetts, Oregon
2024-03-06
Active, closed
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
NCT06239116Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Rhythm Pharmaceuticals, Inc.
Phase 1/2
111
Alabama, Illinois, Massachusetts, Tennessee, Texas, Utah
2024-03-05
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Florida, Georgia, Massachusetts, Missouri, New York, Texas
2024-03-05
Recruiting
Takeda
Phase 3
50
Arizona, California, Colorado, Florida, Indiana, Iowa, Massachusetts, Michigan
2024-03-01
By invitation
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
NCT06245031Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia, Mild
Cognito Therapeutics, Inc.
Not applicable
402
Arizona, California, Colorado, Florida, Georgia, Illinois, Maine, Massachusetts
2024-02-29
Active, closed
Acumen Pharmaceuticals
Phase 2
542
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Mississippi
2024-02-29
Recruiting
Daiichi Sankyo
Phase 2/3
860
Alaska, Connecticut, Florida, Indiana, Kentucky, Massachusetts, Missouri, New Jersey
2024-02-27
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant
OnKure, Inc.
Phase 1
200
California, Colorado, Massachusetts, Nevada, New York, Tennessee, Virginia, Washington
2024-02-26
Active, closed
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
NCT06245915Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
Arsenal Biosciences, Inc.
Phase 1/2
37
Arizona, California, Florida, Iowa, Massachusetts, New York, Texas, Utah
2024-02-26
Recruiting
Skyline Therapeutics (US) Inc.
Phase 1/2
68
Florida, Massachusetts, Texas, Virginia
2024-02-23
Active, closed
Dianthus Therapeutics
Phase 2
65
Arizona, California, Connecticut, Florida, Illinois, Kansas, Kentucky, Massachusetts
2024-02-23
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Alabama, Arizona, California, Florida, Georgia, Massachusetts, Minnesota, Nebraska
2024-02-22
Active, closed
Daiichi Sankyo
Phase 1
210
California, Florida, Hawaii, Illinois, Massachusetts, New York, North Carolina, Ohio
2024-02-22
Active, closed
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT05996003Duchenne Muscular Dystrophy, Exon 44, DMD
DrugBrogidirsen
NS Pharma, Inc.
Phase 2
20
Colorado, Georgia, Illinois, Kansas, Massachusetts, New York, Ohio, Pennsylvania
2024-02-22
Recruiting
Pulmonx Corporation
Not applicable
200
Arizona, Colorado, Connecticut, Florida, Illinois, Kentucky, Massachusetts, Michigan
2024-02-22
Recruiting
Sonavex, Inc.
Not applicable
304
Alabama, Arizona, Florida, Illinois, Kansas, Massachusetts, Michigan, New Jersey
2024-02-21
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Alaska, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Minnesota
2024-02-21
Active, closed
Parkinson's Disease Progression Study
NCT06219629Parkinson Disease
Koneksa Health
Observational
82
Colorado, Florida, Georgia, Kansas, Massachusetts, Michigan, Nevada
2024-02-20
By invitation
Gradient Denervation Technologies
Not applicable
50
Illinois, Massachusetts, North Carolina, South Carolina, Texas, Wisconsin
2024-02-20
Active, closed
Pfizer
Phase 1
100
Florida, Georgia, Indiana, Maryland, Massachusetts, Nebraska, New Hampshire, New Jersey
2024-02-20
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 1/2
47
California, Florida, Kansas, Massachusetts, Missouri, North Carolina, Pennsylvania, Virginia
2024-02-20
Active, closed
Tourmaline Bio, Inc., a Novartis Company
Phase 2
79
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Nevada, New Jersey
2024-02-19
Recruiting
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
NCT04706013Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Medicure
Phase 3
15
Alabama, California, Colorado, Massachusetts, North Carolina, Ohio
2024-02-16
Recruiting
Cabaletta Bio
Phase 1/2
28
California, Connecticut, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2024-02-16
Active, closed
AstraZeneca
Phase 2
58
Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-02-13
Recruiting
argenx
Observational
100
California, Illinois, Massachusetts, Minnesota, Ohio, Pennsylvania
2024-02-13
Recruiting
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor
Frontier Medicines Corporation
Phase 1/2
403
California, Florida, Indiana, Kansas, Massachusetts, Michigan, Pennsylvania, Texas
2024-02-12
Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma
DrugT-Bren
SystImmune Inc.
Phase 1
280
Alabama, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2024-02-09
Recruiting
OnCusp Therapeutics, Inc.
Phase 1
263
Colorado, Connecticut, Florida, Massachusetts, Michigan, New York, Oklahoma, Tennessee
2024-02-09
Active, closed
Lantheus Medical Imaging
Phase 4
274
Alabama, California, Georgia, Iowa, Maryland, Massachusetts, Michigan, Missouri
2024-02-08
Active, closed
Autus Valve Pivotal Study
NCT05006404Congenital Heart Disease
Edwards Lifesciences
Not applicable
62
California, Colorado, Georgia, Illinois, Massachusetts, Michigan, New York, North Carolina
2024-02-05
Active, closed
ReCode Therapeutics
Phase 2
128
Alabama, Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina
2024-02-01
Active, closed
Registry of the Patient Experience for Carpal Tunnel Release
NCT06071468Carpal Tunnel Syndrome, CTS
Sonex Health, Inc.
Observational
1,424
Alabama, Arizona, Connecticut, Florida, Indiana, Massachusetts, Michigan, Minnesota
2024-01-26
Active, closed
AbbVie
Observational
427
Alabama, Arizona, California, District of Columbia, Florida, Illinois, Louisiana, Massachusetts
2024-01-24
Active, closed
Bristol-Myers Squibb
Phase 4
63
California, Georgia, Massachusetts, Ohio, Pennsylvania, Texas, Utah
2024-01-24
Recruiting
STIMIT Activator 1 IDE Study
NCT05883163Diaphragm Issues
Stimit AG
Not applicable
40
Connecticut, Massachusetts, Virginia
2024-01-24
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Keytruda·Pembrolizumab
AstraZeneca
Phase 1/2
161
California, Florida, Georgia, Massachusetts, New York, Pennsylvania, Texas
2024-01-23
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Alabama, California, Colorado, Connecticut, Florida, Massachusetts, New York, Tennessee
2024-01-23
Recruiting
NextPoint Therapeutics, Inc.
Phase 1
144
Maryland, Massachusetts, New York, Texas, Virginia
2024-01-22
Active, closed
Avidity Biosciences, Inc.
Phase 2
39
Arkansas, California, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Texas
2024-01-22
Recruiting
RedDress Ltd.
Not applicable
110
California, Florida, Illinois, Indiana, Massachusetts, Minnesota, New York, Pennsylvania
2024-01-20
Recruiting
BioMarin Pharmaceutical
Observational
200
Colorado, Georgia, Illinois, Indiana, Louisiana, Massachusetts, Oregon, Pennsylvania
2024-01-20
Active, closed
Bolt Medical
Not applicable
426
California, Colorado, Florida, Georgia, Massachusetts, Michigan, Minnesota, Mississippi
2024-01-19
Recruiting
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
NCT06171750Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor
DrugsTolododekin alfa·Cemiplimab
Ankyra Therapeutics, Inc
Phase 1
97
Maryland, Massachusetts, Oregon, Pennsylvania
2024-01-19
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Michigan, Montana
2024-01-18
Active, closed
TRYP Therapeutics
Phase 2
14
Massachusetts
2024-01-17
Active, closed
Merit Medical Systems, Inc.
Not applicable
264
California, District of Columbia, Georgia, Illinois, Massachusetts, Missouri, New Jersey, New York
2024-01-16
Recruiting
NorthSea Therapeutics B.V.
Phase 2
36
Arizona, California, District of Columbia, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2024-01-15
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana, Massachusetts
2024-01-11
Active, closed
Tenax Therapeutics, Inc.
Phase 3
230
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2024-01-10
Recruiting
Gilead Sciences
Phase 1
278
Massachusetts, New York, Texas
2024-01-09
Recruiting
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
NCT06662188SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
Jaguar Gene Therapy, LLC
Phase 1/2
6
Illinois, Massachusetts, New York
2024-01-07
Active, closed
HistoSonics, Inc.
Not applicable
67
California, Connecticut, Florida, Maryland, Massachusetts, New York, Ohio, Texas
2024-01-04
Recruiting
Incyte Corporation
Phase 1
710
Arizona, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, New York
2024-01-04
Active, closed
RECORDATI GROUP
Phase 2
93
California, Illinois, Louisiana, Maryland, Massachusetts, Minnesota, New York, Tennessee
2024-01-04
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 1/2
85
Massachusetts, New York, Ohio
2024-01-04
Recruiting
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
NCT06001827Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure
VenoStent
Not applicable
600
Arizona, California, Florida, Indiana, Kentucky, Massachusetts, Minnesota, Missouri
2024-01-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Arizona, California, Colorado, Massachusetts, Michigan, Nevada, New York, North Carolina
2023-12-31
Recruiting
Daiichi Sankyo
Phase 3
250
Florida, Massachusetts, New Jersey
2023-12-30
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Arizona, California, Florida, Massachusetts, Minnesota, Nebraska, New York, Rhode Island
2023-12-29
Recruiting
Liquidia Technologies, Inc.
Observational
80
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kentucky, Massachusetts
2023-12-28
Recruiting
CytoAgents, Inc.
Phase 1/2
54
California, Georgia, Massachusetts, North Carolina, Pennsylvania, Washington
2023-12-28
Recruiting
Axsome Therapeutics, Inc.
Phase 4
350
California, Florida, Georgia, Illinois, Kansas, Louisiana, Massachusetts, Missouri
2023-12-27
Recruiting
IO Biotech
Phase 2
60
Connecticut, Massachusetts, Virginia
2023-12-21
Active, closed
Bristol-Myers Squibb
Phase 3
190
Iowa, Massachusetts, New York, Washington
2023-12-21
Recruiting
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT06154252Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy
Cabaletta Bio
Phase 2/3
74
California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2023-12-20
Recruiting
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
NCT06118086Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
DrugREM-422
Remix Therapeutics
Phase 1/2
125
California, Florida, Massachusetts, Michigan, New York, Tennessee, Texas
2023-12-20
Recruiting
Ascentage Pharma Group Inc.
Phase 3
400
Arizona, California, Florida, Illinois, Massachusetts, Michigan, North Carolina, Texas
2023-12-20
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2023-12-20
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 3
200
California, Florida, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2023-12-20
Recruiting
Contraceptive Efficacy Study of Ovaprene
NCT06127199Contraception
Daré Bioscience, Inc.
Not applicable
656
Arizona, California, Colorado, Georgia, Hawaii, Louisiana, Maryland, Massachusetts
2023-12-19
Active, closed
AbbVie
Phase 3
614
Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2023-12-19
Recruiting
Biogen
Observational
20
California, Massachusetts, New York
2023-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Arizona, California, Colorado, Florida, Georgia, Kentucky, Maine, Massachusetts
2023-12-15
Recruiting
Regeneron Pharmaceuticals
Phase 3
904
Arizona, California, Florida, Indiana, Kentucky, Maryland, Massachusetts, Michigan
2023-12-13
Active, closed
Deciphera Pharmaceuticals, LLC
Phase 3
54
California, Connecticut, Florida, Maryland, Massachusetts, Minnesota, New York, Ohio
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
822
Arizona, California, Indiana, Massachusetts, Michigan, Mississippi, New York, North Carolina
2023-12-12
Rows per page Showing 501–1000 of 1830
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/massachusetts?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,830 of those studies with a site in Massachusetts.

How many clinical trials are recruiting in Massachusetts?

953 of the 1,830 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 43 have not yet opened recruitment, 776 are active but closed to new participants, and 58 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.